Please use this identifier to cite or link to this item:
Title: Endothelial dysfunction and covid-19 (Review)
Authors: Daher, Jalil 
Affiliations: Department of Biology 
Keywords: Angiotensin converting enzyme 2
Angiotensin converting enzyme inhibitor
Angiotensin II
Angiotensin receptor blocker
Cardiovascular disease
Endothelial dysfunction
Plasminogen activator inhibitor-1
Reactive oxygen species
Renin-angiotensin-aldosterone system
Issue Date: 2021
Part of: Biomedical reports
Volume: 15
Issue: 6
It is hypothesized that several comorbidities increase the severity of COVID-19 symptoms. Cardiovascular disease including hypertension was shown to play a critical role in the severity of COVID-19 infection by affecting the survival of patients with COVID-19. Hypertension and the renin-angiotensin-aldosterone system are involved in increasing vascular inflammation and endothelial dysfunction (ED), and both processes are instrumental in COVID-19. Angiotensin-converting enzyme 2 is an essential component of the renin-angiotensin-aldosterone system and the target receptor that mediates SARS-CoV-2 entry to the cell. This led to speculations that major renin-angiotensin-aldosterone system inhibitors, such as angiotensin receptor blockers and angiotensin-converting enzyme inhibitors might affect the course of the disease, since their administration enhances angiotensin-converting enzyme (ACE)2 expression. An increase in ACE2 activity could reduce angiotensin II concen-tration in the lungs and mitigate virus-driven lung injury. This could also be associated with a reduction in blood coagulation, which plays a critical role in the pathogenesis of SARS-CoV-2; of note, COVID-19 is now regarded as a disorder of blood clotting. Therefore, there is an urgent need to better understand the effect of targeting ACE2 as a potential treatment for SARS-CoV-2 driven injury, and in alleviating COVID-19 symptoms by reversing SARS-CoV-2-induced excessive coagulation and fatalities. Ongoing therapeutic strategies that include recombinant human ACE2 and anti-spike monoclonal antibodies are essential for future clinical practice in order to better understand the effect of targeting ED in COVID-19.
ISSN: 20499434
DOI: 10.3892/BR.2021.1478
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Department of Biology

Show full item record

Record view(s)

checked on Jul 3, 2022

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.